Keros CEO exercises options for 55,000 shares

Keros Therapeutics chief executive officer Jasbir Seehra exercised employee stock options to acquire 55,000 shares of common stock at an exercise price of $0.30 per share on April 2, 2026.

Rhea-AI Filing Summary

Keros Therapeutics chief executive officer Jasbir Seehra exercised employee stock options to acquire 55,000 shares of common stock at an exercise price of $0.30 per share on April 2, 2026. These options were immediately exercisable. Following the transaction, he directly owned 440,708 shares of common stock.

Insider Trade Summary

55,000 shares exercised/converted

Exercise 2 txns

Insider Seehra Jasbir

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	55,000	$0.00	$0.00
Exercise	Common Stock	55,000	$0.30	$17K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 197,444 contracts (Direct); Common Stock — 440,708 shares (Direct)

Footnotes (1)

1. F1. Immediately exercisable.

Key Figures

Options exercised: 55,000 shares Exercise price: $0.30 per share Common shares after transaction: 440,708 shares +2 more

5 metrics

Options exercised 55,000 shares Employee stock options exercised on April 2, 2026

Exercise price $0.30 per share Strike price for the 55,000 exercised options

Common shares after transaction 440,708 shares Direct common stock holdings after April 2, 2026 transaction

Option security shares after exercise 197,444 options Total shares following transaction for the option security

Option expiration date March 25, 2028 Expiration date of the exercised employee stock option

Key Terms

Employee Stock Option (Right to Buy), Exercise or conversion of derivative security, Common Stock, Immediately exercisable

4 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Immediately exercisable financial

"footnote: Immediately exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Keros Therapeutics (KROS) report for Jasbir Seehra?

Jasbir Seehra exercised employee stock options to acquire 55,000 shares of Keros Therapeutics common stock at $0.30 per share. The transaction occurred on April 2, 2026 and reflects an option exercise, not an open-market purchase or sale.

At what price did the Keros Therapeutics CEO exercise his stock options?

The Keros Therapeutics CEO exercised stock options at an exercise price of $0.30 per share. This price reflects the pre-agreed option strike, not the market price, and was used to acquire 55,000 shares of common stock through the option exercise.

How many Keros Therapeutics shares does Jasbir Seehra hold after this Form 4 transaction?

After the reported transaction, Jasbir Seehra directly holds 440,708 shares of Keros Therapeutics common stock. This figure comes from the Form 4 field labeled total shares following transaction for the common stock entry dated April 2, 2026.

Was the Keros Therapeutics CEO’s Form 4 transaction a buy or a sell?

The Form 4 shows an option exercise classified as an acquisition, not an open-market buy or sale. Code M indicates exercise or conversion of a derivative security, and no sale (code S) or purchase (code P) transactions were reported in this filing.

What type of security did the Keros CEO exercise to receive common stock?

The CEO exercised an Employee Stock Option (Right to Buy) that was immediately exercisable. Exercising this derivative security for 55,000 underlying shares at a $0.30 exercise price resulted in the acquisition of 55,000 shares of Keros Therapeutics common stock.

When do the exercised Keros Therapeutics stock options expire?

The employee stock options that were exercised to acquire 55,000 shares had an expiration date of March 25, 2028. The Form 4 notes they were immediately exercisable, and the exercise occurred on April 2, 2026, well before the stated expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/06/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seehra Jasbir

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		M		55,000	A	$0.3	440,708	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$0.3	04/02/2026		M			55,000	(1)	03/25/2028	Common Stock	55,000	$0	197,444	D

Explanation of Responses:

1. Immediately exercisable.

	/s/ Jasbir Seehra	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)